Dual Variable Domain Immunoglobulins for Bispecific Antibody Assembly
Solution Overview
Problem
Current methods for producing bispecific antibodies face challenges such as molecular heterogeneity, reduced production yields, and increased immunogenicity due to the need for sophisticated purification processes and mutational modifications, which affect their stability and efficacy.
Innovation Solution
Development of Dual Variable Domain (DVD) binding proteins with specific linker sequences that allow for high-affinity binding to multiple antigens, enabling efficient production and purification while maintaining antigen-binding activity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If quadroma technology is used to produce bispecific antibodies, then two different antigen specificities can be achieved, but molecular heterogeneity increases and production yield decreases
Solution Approach 1:
The antibody is divided into separate single-chain Fv (scFv) domains that can be independently designed and assembled. Each scFv contains a variable heavy (VH) and variable light (VL) domain connected by a linker, allowing controlled pairing to achieve desired antigen specificities while maintaining molecular homogeneity through defined assembly pathways.
Solution Approach 2:
A standardized linker peptide serves as an intermediary component connecting VH and VL domains. This mediator enables controlled dimerization and pairing of antibody chains, ensuring proper assembly into homogeneous bispecific antibodies while maintaining the desired antigen binding specificities.
2Adaptability or versatility
If chemical conjugation is used to produce bispecific antibodies, then antigen binding can be achieved, but molecular heterogeneity increases
Solution Approach 1:
The patent replaces chemical conjugation methods with a recombinant DNA-based expression system. Antibody chains are produced genetically with defined sequences and assembled through controlled cellular mechanisms rather than random chemical reactions, eliminating molecular heterogeneity while maintaining antigen binding capabilities.
3Adaptability or versatility
If hetero-bifunctional crosslinkers are used to couple parental antibodies, then bispecific antibody formation is achieved, but production yield decreases and purification complexity increases
Solution Approach 1:
The antibody chains are designed with self-complementary features including standardized linkers and domain structures that enable autonomous assembly into functional bispecific antibodies. The system self-organizes through controlled pairing of VH and VL domains without requiring external crosslinking agents or complex purification procedures.
4Adaptability or versatility
If tandem scFv molecules are constructed with long linkers, then antigen binding is achieved, but soluble expression in bacteria becomes difficult
Solution Approach 1:
The patent optimizes linker parameters including length, amino acid composition, and flexibility to achieve the right balance. Linkers are designed with specific characteristics (e.g., charged residues, hydrophilic properties) that prevent aggregation and promote soluble expression in bacterial systems while maintaining antigen binding functionality.
Data Source
AI summary
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.